Medication-assisted treatment, along with group therapy, found to improve inhibitory control in heroin addiction

April 30 2024

Inhibitory control brain activity increases from baseline to follow-up in the iHUD group compared with the HC group. a,b, Right aPFC (a) and right dPFC (b) activity during successful versus failed stops showed significant increases from baseline to follow-up in the iHUD group compared with the HC group.
In line with their previous work, researchers from the Icahn School of Medicine at Mount Sinai showed that individuals with heroin use disorder have lower activity in the anterior and dorsolateral PFC when performing an inhibitory control task compared with healthy controls.

Importantly, they revealed that 15 weeks of medication-assisted therapy, which included supplemental group therapy, improves impaired function of the anterior and dorsolateral PFC during an inhibitory control task among the group of participants with heroin use disorder, suggesting a time-dependent recovery of inhibitory control and PFC function in individuals with heroin use disorder after such a treatment intervention.

The study is published in Nature Mental Health.

Opioid (including heroin) overdose-related deaths continue to increase at staggering rates among adults in the United States. Inhibitory control—the ability to suppress unwanted behaviors, such as drug use, despite substantial negative consequences and a desire to quit—is impaired in individuals with drug addiction and is accompanied by functional deactivations in the prefrontal cortex (PFC), a brain region that subserves self-control processes.

In this study, 26 inpatient individuals with heroin use disorder undergoing medication-assisted treatment and 24 demographically-matched healthy controls were recruited for a longitudinal task-based functional MRI (fMRI) study. Participants attended two fMRI sessions, separated by 15 weeks of medication-assisted inpatient treatment for
individuals with heroin use disorder and a comparable time interval for healthy controls.

During fMRI, the study participants performed a stop-signal task—a well-validated tool for estimating brain function during inhibitory control behavior. During the task, study participants responded to directional arrow stimuli and withheld their responses when the arrow occasionally turned red (the stop signal). In addition to showing increased activity in the PFC regions after 15 weeks of inpatient treatment, the increased activity correlated with better behavioral performance in the stop-signal task by individuals with heroin use disorder.

"Overall, our findings identify the anterior and dorsolateral PFC regions as potentially amenable to targeted interventions to potentially expedite their recovery during inhibitory control, which may have translational value to help inform future treatment methods," says Ahmet O. Ceceli, Ph.D., senior postdoctoral fellow and lead author of the paper.

"More research is needed to determine if there is a specific aspect of inpatient treatment that substantially contributes to the improvement and to examine other specific factors. For example, our research team plans to test whether the recovery effects we observed in this study are attributable to the mindfulness-based intervention that was part of the supplemental group therapy intervention," says Rita Z. Goldstein, Ph.D., Professor of Psychiatry and Neuroscience at Icahn Mount Sinai and senior author of the paper.
